Literature DB >> 17335559

Respiratory syncytial virus replication is prolonged by a concomitant allergic response.

A Hassantoufighi1, M Oglesbee, B W M Richter, G A Prince, V Hemming, S Niewiesk, M C Eichelberger.   

Abstract

Epidemiological studies show an association between early exposure to respiratory syncytial virus (RSV) and the development or exacerbation of asthma. This idea is supported by studies in mice that demonstrate worsened airway hyper-reactivity (AHR) when RSV-infected animals are exposed to allergen. The effect of allergen on RSV disease, however, has not been reported. Cotton rats (Sigmodon hispidus) that have been used as a model to study RSV pathogenesis were sensitized to extracts of Aspergillus fumigatus (Af), a common household mould. The allergic response to Af included eosinophilia, formation of granulomas and induction of Th2 type cytokines. RSV infection prior to allergen challenge resulted in exacerbation of the inflammatory response as well as increased airway responsiveness to methacholine. The exacerbated response was indeed dependent on virus replication. Virus replication in turn was influenced by the allergic response, with persistence in the noses for 2 days longer in animals challenged with allergen. This diminished clearance corresponded to decreased induction of mRNA for IFN-gamma, a Th1-type cytokine that is characteristic of viral infection. Treatment of RSV-infected Af-challenged animals with recombinant IFN-gamma reduced the allergic inflammatory response as well as the relative levels of Th1 and Th2 cytokine mRNA. However, this treatment did not reduce airway reactivity, showing that these pathologic and physiologic measures of exacerbated disease are independent. We speculate that the reciprocal effect of the allergic response on viral immunity may benefit the host by limiting exacerbation of physiologic responses that are IFN-gamma-dependent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17335559      PMCID: PMC1868883          DOI: 10.1111/j.1365-2249.2007.03341.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Critical roles for interleukin-4 and interleukin-5 during respiratory syncytial virus infection in the development of airway hyperresponsiveness after airway sensitization.

Authors:  J Schwarze; G Cieslewicz; A Joetham; T Ikemura; M J Mäkelä; A Dakhama; L D Shultz; M C Lamers; E W Gelfand
Journal:  Am J Respir Crit Care Med       Date:  2000-08       Impact factor: 21.405

2.  Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

Authors:  N Sigurs; R Bjarnason; F Sigurbergsson; B Kjellman
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

3.  Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus).

Authors:  G A Prince; J P Prieels; M Slaoui; D D Porter
Journal:  Lab Invest       Date:  1999-11       Impact factor: 5.662

4.  Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma.

Authors:  E Crimi; A Spanevello; M Neri; P W Ind; G A Rossi; V Brusasco
Journal:  Am J Respir Crit Care Med       Date:  1998-01       Impact factor: 21.405

5.  Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice.

Authors:  S M van Schaik; N Obot; G Enhorning; K Hintz; K Gross; G E Hancock; A M Stack; R C Welliver
Journal:  J Med Virol       Date:  2000-10       Impact factor: 2.327

6.  NF-kappa B activation in airways modulates allergic inflammation but not hyperresponsiveness.

Authors:  Matthew E Poynter; Roy Cloots; Tiest van Woerkom; Kelly J Butnor; Pamela Vacek; Douglas J Taatjes; Charles G Irvin; Yvonne M W Janssen-Heininger
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

7.  Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice.

Authors:  R S Peebles; J R Sheller; R D Collins; A K Jarzecka; D B Mitchell; R A Parker; B S Graham
Journal:  J Med Virol       Date:  2001-02       Impact factor: 2.327

8.  The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production.

Authors:  Azzeddine Dakhama; Jung-Won Park; Christian Taube; Anthony Joetham; Annette Balhorn; Nobuaki Miyahara; Katsuyuki Takeda; Erwin W Gelfand
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

9.  Interleukin-10 modulates the severity of hypersensitivity pneumonitis in mice.

Authors:  G Gudmundsson; A Bosch; B L Davidson; D J Berg; G W Hunninghake
Journal:  Am J Respir Cell Mol Biol       Date:  1998-11       Impact factor: 6.914

10.  Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells.

Authors:  Everett H Meyer; Sho Goya; Omid Akbari; Gerald J Berry; Paul B Savage; Mitchell Kronenberg; Toshinori Nakayama; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-14       Impact factor: 11.205

View more
  6 in total

Review 1.  Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.

Authors:  Barney S Graham
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Viral disruption of olfactory progenitors is exacerbated in allergic mice.

Authors:  R Ueha; S Mukherjee; S Ueha; D E de Almeida Nagata; T Sakamoto; K Kondo; T Yamasoba; N W Lukacs; S L Kunkel
Journal:  Int Immunopharmacol       Date:  2014-07-02       Impact factor: 4.932

Review 3.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

Review 4.  Animal models of virus-induced chronic airway disease.

Authors:  Louis A Rosenthal
Journal:  Immunol Allergy Clin North Am       Date:  2010-09-24       Impact factor: 3.479

5.  Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells.

Authors:  Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Yu-Jin Jung; Youri Lee; Jong Seok Lee; Yu-Na Lee; Soojin Park; Sang-Moo Kang
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 6.  Response to infections in patients with asthma and atopic disease: an epiphenomenon or reflection of host susceptibility?

Authors:  Kristina M James; R Stokes Peebles; Tina V Hartert
Journal:  J Allergy Clin Immunol       Date:  2012-08       Impact factor: 10.793

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.